- February 3, 2021
- Posted by: Swiss Growth Forum
- Categories: Events, Forum, News, Roadshow
The Post Pandemic Recovery SPAC is pleased to announce that internationally respected investor Josh Mailman plans to join the Post Pandemic SPAC’s sponsor group as the soon to be listed entity aims to fund an acquisition of Napo EU. Napo EU’s stated intention is to seek Europewide approval for crofelemer in Europe, a pharmaceutical already successfully marketed and distributed in the US by Jaguar Health, Inc.’s subsidiary Napo, Inc., under the brand umbrella Mytesi.
Josh is Founder and Managing Director of Serious Change L.P., a $100M sole L.P. impact investment vehicle started in 2006. He serves on the board of the following companies: Giving Assistant, Spud (advisory), Social Imprints, HowGood (advisory) and the following non-profits: the Mailman School of Public Health, Echoing Green, the Sigrid Rausing Trust U.K. and the Threshold Foundation .
Josh Mailman founded Social Venture Network ( now Social Venture Circle ) with Wayne Silby of Calvert Group in 1987. He also started the Threshold Foundation (1981) and Business for Social Responsibility (1992).
The Post Pandemic Recovery SPAC (www.postpandemicspac.com) is the brainchild of international investment banker and investor relations specialist Andreea Porcelli who has assumed the role of the SPAC’s Chief Executive Officer alongside her ongoing Swiss Growth Forum activities. Once funded, the SPAC will be listed on AIM Italia with a stated intention of acquiring Napo EU which will in turn purchase the European licences to crofelemer on an exclusive, long-term basis. Some market commentators estimate that Napo EU could generate around US$1billion in sales revenue for crofelemer within 5-years of being approved in the region.
“We are extremely excited that someone with Josh Mailman’s ability, experience and positive reputation has shown willingness to come on board,” states Andreea Porcelli. “With an ability to offer wise counsel, he is not only the kind of investor who this SPAC needs at an early stage but he should also offer an important endorsement of the Post Pandemic Recovery SPAC’s efficacy and relevance. Smarter investors may well be keen to take note of this important news.”